We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 126.50 | 123.00 | 130.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2021 to Apr 2024
TIDMRUA
RNS Number : 8096V
RUA Life Sciences PLC
16 December 2021
RUA Life Sciences plc
("RUA", the "Company" or the "Group")
Unaudited Interim Results
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon (TM) ) , today announces its unaudited interim results for the six months ended 30 September 2021.
Highlights:
-- 12% increase in Revenues to GBP708,000 (H1 2020: GBP631,000) -- Continued investment in R&D activities
-- Strong cash position at GBP4.8 million (30 September 2020: GBP1.0 million, 31 March 2021: GBP6.3 million)
-- Investment in capital equipment for business expansion -- Strengthened senior management team -- Delay in regulatory process of graft approval (as previously announced) -- Continued progress on heart valve project
Bill Brown, Chairman of RUA Life Sciences, commented:
"The change to the regulatory process for the vascular graft range is clearly a major disappointment for both the Company and its shareholders. We remain confident that approval remains a question of "when" and not "if". Progress in the other parts of the business remains on track."
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
David Richmond, CEO Tel: +44 (0)1294 317073
Shore Capital (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7408 4080
Tom Griffiths/David Coaten
Cenkos Securities plc (Joint Broker) Tel: +44 (0)20 7397 8900
Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon (TM) , the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-Eon (TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
Hot Features
Premium
RUA Medical End-to-end contract developer and manufacturer
: of medical devices and implantable fabric specialist.
RUA Biomaterials Licensor of Elast-Eon (TM) polymers to the medical
: device industry.
RUA Vascular: Development of large bore polymer sealed grafts
and soft tissue patches.
RUA Structural Development of tri leaflet polymeric heart valves.
Heart :
A copy of this announcement will be available shortly at www.rualifesciences.com/investor-relations/regulatory-news-alerts .
CHAIRMAN'S STATEMENT
I set out below an overview of the unaudited consolidated interim results of RUA Life Sciences Plc for the six months to 30 September 2021 together with an update on more recent progress and events. The period has been one of continued investment in the business and the new product pipeline in particular.
Unaudited interim results for the six months to 30 September 2021
The results set out below have consolidated the results of RUA Medical Devices Limited with the polymer licensing business and the R&D pipeline activities of the group. Total revenues reported of GBP708,000 represents an increase of 12% over the same period in the previous year. Third party contract manufacturing revenues increased 33% year on year to GBP552,000 reflecting bounce back in elective surgeries, particularly in the US. Polymer license and royalty fees represented the balance of group revenues of GBP156,000. This figure is around GBP60,000 down on the previous year but disguises a growth in the underlying volumes of Elast-Eon(TM) being shipped by our manufacturing licensee, and is masked by an adverse exchange movement and a timing difference in the periods in which, as previously announced, royalties from a major licensee will be recognised in this financial year. We anticipate this timing difference to reverse during the second half of the current finncial year. The reduction in other income from GBP239,000 to GBP37,000 is represented by a Covid support grant of GBP150,000 received last year together with some employees having been furloughed in that year.
RUA continued to expense all R&D investment through its profit and loss account rather than capitalise the investment. R&D costs are included in administrative expenses which amounted to GBP1,658,000 during the period, an increase of GBP149,000 over the preceding six month period which in turn was GBP328,000 higher than the first half of last year. R&D expenditure during the half year amounted to some GBP515,000, a doubling of the run rate last year.
Overall, the increased loss before tax for the period of GBP1,315,000 (2020: GBP622,000) is attributed to a combination of increased R&D activities, further investment in the infrastructure to support growth and the reduction in Covid grant support.
The Group retains a cash balance at the period end of GBP4,763,000 (2020: GBP1,009,000) having invested further in capital equipment and made the final payment of the deferred consideration payable for the acquisition of RUA Medical.
RUA Vascular - Regulatory Strategy
The focus over the period was concluding a not inconsiderable amount of work required in preparation for the recent 510(k) regulatory submission to the FDA for the range of Elast-Eon(TM) sealed vascular grafts.
The regulatory strategy and testing protocols were set in September 2020 under advice from third party consultants. Much was asked of the RUA team to achieve the demanding timelines for each of product design, development and regulatory testing and these activities were carried out in only 18 months from the acquisition of RUA Medical.
The Company announced in early November 2021 that the 510(k) for the vascular graft range had been submitted to the FDA, but was disappointed to have to announce on 13 December 2021 a delay to the regulatory process. The initial document review has been concluded by the FDA and a lead reviewer appointed. A call was held with the FDA to discuss the Company's submission.
The 510(k) strategy sought approval based on the Company's claim that its device is substantially equivalent to existing products on the market. Having provisionally reviewed the Company's application, the FDA has highlighted that the Company's products introduce novel technology which is unproven in this application, i.e. the incorporation of Elast-Eon(TM) on the outside of the graft to ensure that it is sealed. The standard of data required to support the 510(k) is therefore higher than if the Company was producing a true like-for-like product. The FDA has indicated that it will require human clinical data in order to approve the Company's product. Rather than withdraw the 510(k), the Company has mutually agreed with the FDA to convert its 510(k) submission to a pre-submission or Q-sub. This Q-sub is an interactive discussion between RUA and the FDA to determine the regulatory pathway to approval in the US and allows the Company to negotiate with the FDA over the data required to support a future 510(k) clearance. Through this route, the Company will receive a full written response from the FDA in January 2022, which will allow detailed discussions to take place thereafter with the FDA.
Until the written response is received from the FDA, and the additional data requirements understood, it is not currently possible to provide accurate guidance on the revised regulatory pathway.
It is however clear that human clinical data will be required for FDA clearance to enable the Company to market the grafts. It had always been in our plans to undertake a trial or study once 510(k) clearance had been received. This was planned for marketing and regulatory reasons. From a marketing perspective, US based surgeons and hospitals, other than the Key Opinion Leaders, would wish to see clinical data to support the acceptance cascade of the new device. Additionally, the second target market after the US was planned to be Europe and the regulatory requirements for CE Mark approval necessitates a clinical study.
The revised process will result in an acceleration of the Company's clinical study plans that will serve us well in the long run, by enabling an earlier entry into European and other global markets and providing Sales and Marketing teams with the required clinical data at US market launch to accelerate and drive acceptance and take up of the products.
RUA Vascular - Market Drivers and Production Capacity
Production capacity was being developed to be capable of meeting the market needs of initial marketing samples and provision of clinical devices for the clinical studies, with the scale up production equipment being verified for manufacture to meet the growing demand as study results became available. Additionally, the initial launch would target straight grafts with the aortic root graft to follow.
Over the last few months, the Company has been actively engaged with the surgical and medical device community in both Europe and the USA. This has involved a number of potential substantial OEM companies, carefully chosen European distribution partners plus a lead US importer with experienced US distribution partners. In all cases, the Company has been able to provide product samples and the feedback is now resulting in positive changes to launch plans.
It has become clear that there is an acceptance in the medical and device community of an inevitable switch away from animal sourced products once a surgical fully synthetic graft is available. The opportunity open to RUA is now much more than being just another graft manufacturer with an interesting sealing technology, but to become a very significant player in the surgical graft market. The market has seen little innovation in new surgical graft technology, with most companies focussing on endovascular products whilst continuing to enjoy attractive margins from surgical grafts. RUA has the potential to disrupt this market.
The structural shift towards non-biogenically sealed grafts will happen in Europe too and the Company has observed substantial interest in the product range from surgeons, OEM manufacturers and distribution partnerships. The Company therefore needs to accelerate its work on obtaining regulatory approval for the RUA grafts in Europe where a clinical trial will be required.
There is growing OEM interest in the RUA graft range and the unique one-piece aortic root graft in particular. Not only does the RUA product offer several potential benefits to surgeons, but it provides clear advantages in both manufacturing and sterilising valved conduits. Such are the surgical benefits of combining a graft with a valve, the selling prices of the combined product can be almost double the selling prices of the individual components. Asking a medical device company to change supplier of a key device component is not a simple task due to the regulatory process it will need to go through. With the growing recognition of supply chain risk, the manufacturing benefits of a polymer sealed graft and surgeon impetus, the Board believes that the RUA graft has a significant opportunity for valved conduits.
Aortic root grafts are of much greater added value than the standard straight grafts and as such retail at two to three times the value of a corresponding straight graft.
The anticipated requirement to undertake a clinical study for 510(k) clearance to market not only accelerates the timeframe for a European market launch, but also provides the marketing data to help drive faster market acceptance in the US once approved. The market feedback on the aortic root grafts also helps the Company's manufacturing and production plans to ensure that the higher value products are prioritised for sale once the vascular graft range has received regulatory approval.
RUA Medical
A recent review of the resources available to RUA Medical and competing demands for those resources from group wide development plans has resulted in a slight change to RUA Medical's business model to ensure that priority is given to long term strategic opportunities that can add a minimum of 10 per cent. to RUA Medical revenues together with Group projects.
In line with this revised strategy, RUA Medical has been involved in a long running development project for a global medical device company. The time invested in this project has resulted in a new income stream from manufacturing medical textile components, which is expected to commence in the second half of this financial year and once fully on stream should meet the incremental revenue requirements under the revised strategy.
Sales to the major customer of RUA Medical continue to recover from Covid related elective surgery deferment. Order intake is currently displaying an unusual level of variability making forecasting the level of growth difficult.
RUA Biomaterials
The Company's manufacturing partner, Biomerics, is currently undertaking an expansion of its Elast-Eon(TM) manufacturing capacity and is further increasing marketing activities relating to its polymer offering. Deliveries of polymer to Biomerics customers have seen continued growth over the last few months. It is also pleasing to report that RUA's Intellectual Property portfolio has been enhanced with the granting of a new European patent titled: "Process for the preparation of polyurethane solutions based on silicon-polycarbonate diols."
RUA Structural Heart
The heart valve projects have continued to make good progress with recent manufacturing trials of the 100% polymeric leaflet demonstrating a step change in quality of manufacture and durability potential. The results from those manufacturing trials have confirmed the predictive modelling undertaken prior to the trial thus giving additional confidence that further design and process improvements should again be achieved in manufacture. This valve leaflet low stress design has been replicated utilising a composite material and given the promising results in hydro dynamic testing of the early proof of concept devices, equipment is now being commissioned to manufacture composite valves in a controlled environment. Polymers and non-biogenic valve options are now being openly discussed at influential global cardiothoracic surgical meetings as being the future of heart valves and RUA is being mentioned in those discussions. The Company's strategy is to develop the two technology platforms in parallel to the point of determining the most clinically viable.
Planning for Growth
A little over 18 months ago, the Group acquired RUA Medical which, at the time, was a third-party medical device manufacturer with a focus on new product innovation. While the Group has benefitted from this innovative culture, it must also continue to develop the scale and expertise to meet the needs of a device manufacturer in its own right. The Company recently acquired the industrial unit next door to the Irvine facility and plans are being drawn up to develop a further range of clean room suites required to meet the likely demand for the Company's grafts.
The Board also recognises the need to build the team and I am delighted that the senior executive team at RUA Life Sciences has been further strengthened by two key appointments. Iain Anthony has joined as Director of Clinical and Regulatory Affairs, a non-Board position, and brings a wealth of relevant cardiovascular device experience. In addition, Lachlan Smith has joined as CFO with expertise in implementing the financial and management systems required to control high growth businesses. Subject to the completion of satisfactory due diligence, expected to be completed in January 2022, the Company intends to appoint Lachlan to the Board and will make a further announcement in due course. Both Iain and Lachlan have key roles to play in the business in providing the expertise to lead the revised regulatory strategy and the detailed financial planning to maximise contribution from the vascular range by prioritising both manufacturing efforts and sales focus.
Outlook
It is clearly a disappointment that the 510(k) regulatory path was not as simple as we had hoped and been advised. It is however a relief that the issues relate to substantive equivalence rather than the market need or benefits of the graft range. Rather than obtain US marketing clearance and undertake a soft launch as clinical data is gathered, the clinical data will now be gathered ahead of regulatory approval allowing a fuller launch into both the US and Europe supported with greater clinical evidence available for OEM partners.
The Company will continue to update on its plans as discussions progress with the FDA and it has a clearer view on the likely work packages required and timeframes.
Bill Brown, Chairman
15 December 2021
CONDENSED CONSOLIDATED INTERIM INCOME STATEMENT
Six months ended 30 September 2021
Unaudited Unaudited Audited
Six months Six months Twelve months
to 30 Sep to 30 Sep to 31 Mar
2021 2020 2021
Note GBGBP000 GBGBP000 GBGBP000
----------- ----------- --------------
Revenue 3 708 631 1,528
Cost of sales (180) (134) (276)
----------- ----------- --------------
Gross profit 528 497 1,252
Other income 37 239 279
Administrative expenses (1,658) (1,181) (2,690)
Other expenses:
Share-based payments (68) - (128)
Bad debts written back - - 8
Depreciation & amortisation (145) (175) (272)
----------- ----------- --------------
Total adimistrative
expenses (1,871) (1,356) (3,082)
----------- ----------- --------------
Operating loss (1,306) (620) (1,551)
Finance income/(expense) (9) (2) (43)
----------- ----------- --------------
Loss before taxation (1,315) (622) (1,594)
Taxation 4 13 143
----------- ----------- --------------
Loss attributable to
equity holders of the
parent company (1,311) (609) (1,451)
----------- ----------- --------------
Loss per share (basic
and diluted) - GB Pence 1 (5.91) (3.76) (8.20)
CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION
Unaudited Unaudited Audited
30 Sep 30 Sep
2021 2020 31 Mar 2021
Note GBGBP000 GBGBP000 GBGBP000
Assets
Non-current assets
Goodwill 4 301 - 301
Other intangible assets 5 547 1,013 574
Property, plant and
equipment 6 2,231 1,630 1,952
---------- ---------- ------------
Total non-currents
assets 3,079 2,643 2,827
---------- ---------- ------------
Current assets
Inventories 177 114 85
Trade and other receivables 866 278 949
Cash and cash equivalents 4,763 1,009 6,294
---------- ---------- ------------
Total current assets 5,806 1,401 7,328
---------- ---------- ------------
Total assets 8,885 4,044 10,155
---------- ---------- ------------
Equity
Issued capital 7 1,109 12,650 12,949
Share premium 11,729 5,554 11,729
Capital redemption
reserve 7 11,840 - -
Other reserve (1,629) (1,825) (1,697)
Profit and loss account (15,786) (13,633) (14,475)
---------- ---------- ------------
Total equity attributable
to equity holders of
the parent company 7,263 2,746 8,506
---------- ---------- ------------
Liabilities
Non-current liabilities
Borrowings 305 270 223
Lease liabilities 5 20 124
Deferred tax 159 118 163
Other Liabilities 204 50 40
---------- ---------- ------------
Total non-current liabilities 673 458 550
---------- ---------- ------------
Current liabilities
Borrowings 60 10 23
Lease liabilities 8 8 40
Trade and other payables 847 802 1,016
Other liabilities 34 20 20
---------- ---------- ------------
Total current liabilities 949 840 1,099
---------- ---------- ------------
Total liabilities 1,622 1,298 1,649
---------- ---------- ------------
Total equity and liabilities 8,885 4,044 10,155
---------- ---------- ------------
At 30 September 2021
Unaudited Unaudited Audited
Six months Six months Twelve months
to 30 to 30 to 31 Mar
Sep 2021 Sep 2020 2021
GBGBP000 GBGBP000 GBGBP000
Cash flows from operating activities
Group loss after tax (1,311) (609) (1,451)
Adjustments for:
Fair value gain on acquisition - (21) -
of subsidiary
Other / rounding - 2 -
Depreciation and amortisation 145 175 272
Share-based payments 68 - 128
Interest (income) / expense 7 2 9
Tax credit in year - - (143)
(Increase) / decrease in trade
and other receivables 563 (44) (589)
(Increase) / decrease in inventories (93) - 7
Increase / (decrease) in taxation (4) (13) 122
Increase / (Decrease) in trade
and other payables (471) (47) 231
Net cash flow from operating
actvities (1,096) (555) (1,414)
----------- ----------- --------------
Cash flows from investing activites
Purchase of property, plant &
equipment (397) (310) (620)
Proceeds from disposal of property
plant and equipment - - 18
Acquisition of subsidiary, net
of cash acquired - (354) (341)
Interest received / (paid) (7) (1) (9)
----------- ----------- --------------
Net cash flow from investing
activities (404) (665) (952)
----------- ----------- --------------
Cash flows from financing activities
Proceeds of issue of share capital,
net of issue costs - - 6,462
Proceeds from borrowing - 260 260
Repayment of loans and lease
liabilities (31) (7) (38)
Net cash flow from financing
activities (31) 253 6,684
----------- ----------- --------------
Net increase / (decrease) in
cash and cash equivalents (1,531) (967) 4,318
Cash and cash equivalents at
beginning of period 6,294 1,976 1,976
----------- ----------- --------------
Cash and cash equivalents at
end of period 4,763 1,009 6,294
----------- ----------- --------------
CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENT
Six months ended 30 September 2021
Condensed consolidated interim statement of changes in equity
Issued Capital Profit
share redemption Other and loss Total
capital Share premium reserve reserve account equity
GBGBP000 GBGBP000 GBGBP000 GBGBP000 GBGBP000 GBGBP000
Balance at 31 March 2020 12,574 4,550 - (1,825) (13,024) 2,275
Rounding 1 - - - - 1
Issue of equity share capital
(net of issue costs) 75 1,004 - - - 1,079
--------- ------------- ------------ --------- --------- ---------
Transactions with owners 76 1,004 - - - 1,080
--------- ------------- ------------ --------- --------- ---------
Total comprehensive loss
for the period - - - - (609) (609)
--------- ------------- ------------ --------- --------- ---------
Balance at 30 September 2020 12,650 5,554 - (1,825) (13,633) 2,746
--------- ------------- ------------ --------- --------- ---------
Rounding (1) - - - - (1)
Share-based payments - - - 128 - 128
Issue of equity share capital
- exercise of warrants 8 42 - - - 50
Issue of equity share capital
(net of issue costs) - fundraise 292 6,133 - - - 6,425
--------- ------------- ------------ --------- --------- ---------
Transactions with owners 299 6,175 - 128 - 6,602
--------- ------------- ------------ --------- --------- ---------
Total comprehensive loss
for the period - - - - (842) (842)
--------- ------------- ------------ --------- --------- ---------
Balance at 31 March 2021 12,949 11,729 - (1,697) (14,475) 8,506
--------- ------------- ------------ --------- --------- ---------
Transfer deferred share to
capital redemption reserve (11,840) - 11,840 - - -
Share-based payments - - - 68 - 68
--------- ------------- ------------ --------- --------- ---------
Transactions with owners (11,840) - 11,840 68 - 68
--------- ------------- ------------ --------- --------- ---------
Total comprehensive loss
for the period - - - - (1,311) (1,311)
--------- ------------- ------------ --------- --------- ---------
Balance at 30 September 2021 1,109 11,729 11,840 (1,629) (15,786) 7,263
--------- ------------- ------------ --------- --------- ---------
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
1. BASIS OF PREPARATION
General information
RUA Life Sciences plc is the ultimate parent company of the Group, whose principal activities are the design and manufacture of medical devices and exploiting the value of its IP and know-how.
RUA Life Sciences plc is incorporated and domiciled in the UK and its registered office is c/o Davidson Chalmers Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ.
Basis of preparation
These condensed consolidated interim financial statements are for the six months ended 30 September 2021 and have been prepared with regard to the requirements of IAS 34 on "Interim Financial Reporting". They do not include all of the information required for full financial statements and should be read in conjunction with the audited consolidated financial statements of the Group for the year ended 31 March 2021.
The financial information for the six months ended 30 September 2021 and the comparative figures for the six months ended 30 September 2020 are unaudited. They have been prepared on the basis of the accounting policies set out in the consolidated financial statements of the Group for the year ended 31 March 2021 and, on the recognition, and measurement principles of IFRS in issue as effective at 30 September 2021. The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements.
The figures for the year ended 31 March 2021 have been extracted from the audited statutory accounts which were approved by the Board of Directors on 9 July 2021, prepared under IFRS, received an unqualified audit report, did not contain statements under sections 498(2) and 498(3) of the Companies Act 2006 and have been delivered to the Registrar of Companies.
These condensed consolidated interim financial statements were approved for issue by the Board of Directors on 15 December 2021.
Going concern
The Group will continue to incur further costs as it continues to commercialise its vascular business and continues to pursue its polymeric heart valve through clinical development. After making enquiries, and assuming anticipated cash flows, the Directors expect that the Group's current financial resources will be sufficient to support operations for at least the next 12 months from the date of this announcement. The Group therefore continues to adopt the going concern basis in the preparation of these financial statements.
Loss per share
Loss per share has been calculated on the basis of the result for the period after tax, divided by the number of ordinary shares in issue in the period of 22,184,798. The 30 September 2020 comparative is calculated by reference to the number of ordinary shares in issue at that date which was 16,186,608. The comparative for the year ended 31 March 2021 is calculated by reference to the weighted average number of ordinary shares in issue which were 17,697,120.
2. RELATED PARTY TRANSACTION
At 31 March 2021, the Group had a liability to David Richmond, Group CEO at that date, in respect of deferred consideration to the sum of GBP425,000 for the acquisition of RUA Medical Limited on 1 April 2020. The deferred consideration was settled on 30 April 2021. No interest was payable on the outstanding balance.
David Richmond resigned as a Director of the Company on 31 August 2021.
3. SEGMENTAL REPORTING
The principal activities of the RUA Life Sciences Group are the design and manufacture of medical devices and exploiting the value of its IP and know-how.
Analysis of revenue by income Unaudited Unaudited Audited
stream
Six months Six months Twelve months
to 30 Sep to 30 Sep to 31 Mar
2021 2020 2021
GBGBP000 GBGBP000 GBGBP000
Contract Design & Development 44 - 23
Medical Devices Manufacture
& Sales 508 416 998
Royalty revenue 156 215 507
---------------- ----------- ----------------------------
Total 708 631 1,528
---------------- ----------- ----------------------------
Analysis of revenue by geographical
location Unaudited Unaudited Audited
Six months Six months Twelve months
to 30 Sep to 30 Sep to 31 Mar
2021 2020 2021
GBGBP000 GBGBP000 GBGBP000
Europe 43 79 249
USA 643 533 1,237
RoW 22 19 42
---------------- ----------- ----------------------------
Total 708 631 1,528
---------------- ----------- ----------------------------
The Group's revenue for six months to 30 September 2021 is
segmented as follows:
Unaudited Unaudited Unaudited
Analysis of revenue by income RUA Life RUA Medical
stream Sciences Devices Group Total
Contract Design & Development - 44 44
Medical Devices Manufacture &
Sales - 508 508
Royalty revenue 156 - 156
---------------- ------------------------- --------------
Total 156 552 708
---------------- ------------------------- --------------
Analysis of revenue by geographical
location
Europe - 44 44
USA 134 508 642
RoW 22 - 22
---------------- ------------------------- --------------
Total 156 552 708
---------------- ------------------------- --------------
Unaudited Unaudited Unaudited
Segment Analysis RUA Life RUA Medical Total
Sciences Devices
GBGBP000 GBGBP000 GBGBP000
Consolidated group revenues
from external customers 156 552 708
Contributions to group operating
loss (967) (339) (1,306)
Depreciation 1 117 118
Amortisation of intangible
assets 5 22 27 Segment assets 5,122 3,763 8,885 Segment liabilities 259 1,363 1,622 Intangible assets - goodwill 0 301 301 Other intangible assets 85 462 547 Additions to non-current assets 84 313 397 4. GOODWILL
The final valuation following the acquisition of RUA Medical Devices Limited gave rise to adjustments being required to the value of intangibles recognised in the Interim Report for the six months ended 30 September 2020 (as noted in note 5 below), and led to the following goodwill being recognised:
No impairment review has been carried out in the six-month period.
GBGBP000
Gross carrying amount
Balance at 31 March 2020 -
Acquired through business
combination 301
-----------------
Balance at 31 March 2021 301
-----------------
Impairment -
-----------------
Balance at 30 September
2021 301
-----------------
5. INTANGIBLE ASSETS
Acquired
Intellectual Development Intellectual Customer Technology
Property costs property related based Total
Gross
carrying
amount
At 31 March
2020 - 337 3,325 - - 3,662
Additions 834 - - - - 834
------------ -------------------- ------------ --------------------- ------------------- ----------
At 30
September
2020 834 337 3,325 - - 4,496
Adjustment
following
fair value
exercise
on
aquisition (834) - - 247 141 (446)
Additions - - - - - -
------------ -------------------- ------------ --------------------- ------------------- ----------
At 31 March
2021 - 337 3,325 247 141 4,050
Additions - - - - - -
------------ -------------------- ------------ --------------------- ------------------- ----------
At 30
September
2021 - 337 3,325 247 141 4,050
------------ -------------------- ------------ --------------------- ------------------- ----------
Amortisation
and
impairment
At 31 March
2020 - 316 3,091 - - 3,407
Charge for
the period 62 14 - - - 76
------------ -------------------- ------------ --------------------- ------------------- ----------
At 30
September
2020 62 330 3,091 - - 3,483
Adjustment
following
fair value
exercise
on
aquisition (62) - - 14 7 (41)
Charge for
the period - 4 8 15 7 34
------------ -------------------- ------------ --------------------- ------------------- ----------
At 31 March
2021 - 334 3,099 29 14 3,476
Charge for
the period - 2 4 14 7 27
------------ -------------------- ------------ --------------------- ------------------- ----------
At 30
September
2021 - 336 3,103 43 21 3,503
------------ -------------------- ------------ --------------------- ------------------- ----------
Net book
value
At 30
September
2020 772 7 234 - - 1,013
------------ -------------------- ------------ --------------------- ------------------- ----------
At 31 March
2021 - 3 226 218 127 574
------------ -------------------- ------------ --------------------- ------------------- ----------
At 30
September
2021 - 1 222 204 120 547
------------ -------------------- ------------ --------------------- ------------------- ----------
6. PROPERTY, PLANT AND EQUIPMENT
Land & Plant Office Motor Total
Buildings & Machinery Equipment Vehicles
GBGBP000 GBGBP000 GBGBP000 GBGBP000 GBGBP000
Cost
At 31 March 2020 - - 6 - 6
Acquisition through
business combination
at fair value 590 753 44 - 1,387
Additions 211 118 - - 329
----------- ------------- ----------- ---------- ---------
At 30 September 2020 801 871 50 - 1,722
Adjustment following
fair value exercise (11) 12 - - 1
Additions 154 312 14 28 508
Disposals - (81) (1) - (82)
----------- ------------- ----------- ---------- ---------
At 31 March 2021 944 1,114 63 28 2,149
Additions 28 361 8 - 397
At 30 September 2021 972 1,475 71 28 2,546
----------- ------------- ----------- ---------- ---------
Depreciation
At 31 March 2020 - - 1 - 1
Charge 28 55 8 - 91
----------- ------------- ----------- ---------- ---------
At 30 September 2020 28 55 9 - 92
Adjustment following
fair value exercise 1 5 - - 6
Charge 29 60 10 9 108
Eliminated on disposal - (8) (1) - (9)
----------- ------------- ----------- ---------- ---------
At 31 March 2021 58 112 18 9 197
Charge 29 79 7 3 118
At 30 September 2021 87 191 25 12 315
----------- ------------- ----------- ---------- ---------
Net book value
At 30 September 2020 773 816 41 - 1,630
----------- ------------- ----------- ---------- ---------
At 31 March 2021 886 1,002 45 19 1,952
----------- ------------- ----------- ---------- ---------
At 30 September 2021 885 1,284 46 16 2,231
----------- ------------- ----------- ---------- ---------
Included in the net carrying amount of property plant and equipment are right-of-use assets as follows:
30 September
2021
GBGBP000
Plant & Machinery 147
Motor vehicles 16
-------------
Total right-of-use
assets 163
-------------
7. ISSUED SHARE CAPITAL
During the 6 month period to 30 September 2021 the Company completed the Buy Back of all of its Deferred Shares, details of which were set out in the Circular sent to Shareholders dated 4 June 2021. All of the Deferred Shares acquired have been cancelled. Following the repurchase and cancellation of the Deferred Shares, there are no Deferred Shares in issue and the New Articles have been adopted.
The Company's issued share capital following completion of the Buy Back of all of its Deferred Shares comprises 22,184,798 Ordinary Shares of which none are held in treasury.
8. INTERIM ANNOUNCEMENT
The interim results announcement was released on 16 December 2021. A copy of this Interim Report is also available on the Company's website www.rualifesciences.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR FFEFAIEFSEDE
(END) Dow Jones Newswires
December 16, 2021 02:00 ET (07:00 GMT)
1 Year Aortech Chart |
1 Month Aortech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
